No Data
Remegen Biopharmaceutical (Yantai) Co., Ltd. 2024 Semi-annual Report
Summary of Remegen (Yantai) Co., Ltd.'s 2024 Interim Report
[HK Connect] Remegen (09995) achieved a 75.59% year-on-year increase in revenue during the first half of the year, and a 49.18% increase in research and development expenses.
Remegen (09995) released its 2024 interim report. The report shows that the net income attributable to shareholders of the listed company was -780 million yuan (RMB, same below), compared to -703 million yuan for the same period last year. The basic earning per share was -1.45 yuan. During this period, the company achieved a revenue of 7.42 billion yuan, an increase of 75.59% year-on-year. In terms of research and development, the company continued to increase investment in R&D. The R&D expenses during the reporting period were 0.806 billion yuan, a year-on-year increase of 49.18%. The R&D pipeline further expanded and a large number of research results were achieved, maintaining a leading position in the industry.
Express News | RemeGen H1 Adjusted Net Income RMB -743.4 Million
Express News | RemeGen H1 Revenue RMB 739.7 Million
Express News | RemeGen H1 Gross Profit RMB 570.4 Million
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
No Data
